Decision: Favourable
Study Title:
An Open-label, Sequential, Ascending, Repeated Dose-finding Study of Sarilumab, Administered with Subcutaneous (SC) Injection, in Children and Adolescents, Aged 1 to 17 Years, with Systemic Juvenile Idiopathic Arthritis (sJIA), Followed by an Extension Phase
NREC Code:
21-NREC-CT-003
Decision:
Favourable
Meeting Date:
02/06/2021
Study Type:
CT application
Principal Investigator:
Dr Orla Killeen
PI Institution:
Children's Health Ireland at Crumlin
Sponsor:
Sanofi-aventis Recherche & Développement